CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
593.07MCAD418.69M · vs all stocks (USD)
Revenue (TTM)
293.63MCAD207.29M · vs all stocks (USD)
Profit Margin
-79.22%Beta
2.43xvs all stocks
52-Week Change
-34.98%vs all stocks
Market Capitalization
593.07MCAD418.69M · vs all stocks (USD)
Enterprise Value
506.39MCAD357.49M · vs all stocks (USD)
Forward P/E
-7.71xPrice to Sales (TTM)
2.00xPrice to Book (MRQ)
0.8047xEnterprise to Revenue
1.73xEnterprise to EBITDA
-19.40xGross Margin
27.40%Profit Margin
-79.22%Operating Margin
-21.66%Return on Assets (TTM)
-3.92%Return on Equity (TTM)
-39.51%Revenue (TTM)
293.63MCAD207.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.8240CADUpdated Sep 29, 2026Quarterly Revenue Growth
12.50%Gross Profit (TTM)
83.75MCAD59.12M · vs all stocks (USD)
EBITDA (TTM)
-26.11MCAD-18.43M · vs all stocks (USD)
Net Income (TTM)
-232.63MCAD-164.22M · vs all stocks (USD)
Operating Cash Flow (TTM)
-78.48MCAD-55.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.19MCAD5.07M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CADUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
0.00CADFY2026 · Mar 31, 2026Revenue
284.60MCADFY2026 · Mar 31, 2026Cost of Goods Sold
214.93MCADFY2026 · Mar 31, 2026Gross Profit
69.67MCADFY2026 · Mar 31, 2026Operating Income
-73.11MCAD-51.61M · vs all stocks (USD)
Pre-tax Income
-262.88MCADFY2026 · Mar 31, 2026Income Tax Expense
23.00KCADFY2026 · Mar 31, 2026Net Income
-262.91MCADFY2026 · Mar 31, 2026EBIT
-224.69MCADFY2026 · Mar 31, 2026EBITDA (Income Statement)
-26.14MCADFY2026 · Mar 31, 2026Selling, General & Administrative
122.92MCADFY2026 · Mar 31, 2026Non-operating Interest Income
10.00MCADFY2026 · Mar 31, 2026Non-operating Interest Expense
38.19MCADFY2026 · Mar 31, 2026EPS (Basic)
-0.8800CADFY2026 · Mar 31, 2026EPS (Diluted)
-0.8800CADFY2026 · Mar 31, 2026Basic Shares Outstanding
298.04MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
298.04MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-262.91MCADFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00CADFY2026 · Mar 31, 2026Operating Cash Flow
-113.14MCADFY2026 · Mar 31, 2026Free Cash Flow
-118.47MCADFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
364.68MCADFY2026 · Mar 31, 2026Income Tax Paid
469.00KCADFY2026 · Mar 31, 2026Interest Paid
29.02MCADFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-262.91MCADFY2026 · Mar 31, 2026Depreciation & Amortization
36.47MCADFY2026 · Mar 31, 2026Deferred Taxes (CF)
23.00KCADFY2026 · Mar 31, 2026Stock-based Compensation
4.27MCADFY2026 · Mar 31, 2026Other Non-cash Items
79.61MCADFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
25.68MCADFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
3.71MCADFY2026 · Mar 31, 2026Capital Expenditures
-5.33MCADFY2026 · Mar 31, 2026Net Intangibles (CF)
-620.00KCADFY2026 · Mar 31, 2026Net Acquisitions
-41.54MCADFY2026 · Mar 31, 2026Purchase of Investments
0.00CADFY2026 · Mar 31, 2026Sale of Investments
19.00MCADFY2026 · Mar 31, 2026Other Investing Activity
7.13MCADFY2026 · Mar 31, 2026Net Investing Cash Flow
-20.73MCADFY2026 · Mar 31, 2026Long-term Debt Issuance
207.99MCADFY2026 · Mar 31, 2026Long-term Debt Payments
-221.51MCADFY2026 · Mar 31, 2026Other Financing Charges
-28.24MCADFY2026 · Mar 31, 2026Net Financing Cash Flow
332.41MCADFY2026 · Mar 31, 2026Shares Outstanding
423.02MSharesUpdated Sep 29, 2026Float Shares
422.17MSharesUpdated Sep 29, 2026Shares Short
16.34MSharesUpdated Sep 29, 2026Short Ratio
24.21daysvs all stocks
Short % of Shares Outstanding
3.86%vs all stocks
% Held by Insiders
0.19%vs all stocks
% Held by Institutions
7.98%vs all stocks
Total Cash (MRQ)
337.80MCAD238.48M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7990CADUpdated Sep 29, 2026Total Debt (MRQ)
277.33MCAD195.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4027xCurrent Ratio (MRQ)
3.04xBook Value per Share (MRQ)
1.63CADUpdated Sep 29, 2026Total Assets
1.12BCAD789.78M · vs all stocks (USD)
Total Current Assets
529.47MCADFY2026 · Mar 31, 2026Total Liabilities
421.14MCADFY2026 · Mar 31, 2026Total Non-current Assets
589.27MCADFY2026 · Mar 31, 2026Total Non-current Liabilities
262.69MCADFY2026 · Mar 31, 2026Total Current Liabilities
158.44MCADFY2026 · Mar 31, 2026Cash
126.44MCADFY2026 · Mar 31, 2026Cash Equivalents
238.25MCADFY2026 · Mar 31, 2026Cash & Cash Equivalents
364.68MCADFY2026 · Mar 31, 2026Other Short-term Investments
0.00CADFY2026 · Mar 31, 2026Accounts Receivable
31.24MCADFY2026 · Mar 31, 2026Inventory
110.51MCADFY2026 · Mar 31, 2026Accounts Payable
34.82MCADFY2026 · Mar 31, 2026Short-term Debt
30.56MCADFY2026 · Mar 31, 2026Other Current Liabilities
55.34MCADFY2026 · Mar 31, 2026Long-term Debt
248.15MCADFY2026 · Mar 31, 2026Other Non-current Liabilities
6.35MCADFY2026 · Mar 31, 2026Common Stock (Book)
9.23BCADFY2026 · Mar 31, 2026Retained Earnings
-11.14BCADFY2026 · Mar 31, 2026Total Shareholders' Equity
697.59MCAD492.47M · vs all stocks (USD)
52-Week Low
1.18CADUpdated Sep 29, 202652-Week High
3.28CADUpdated Sep 29, 202652-Week Change
-34.98%vs all stocks
Beta
2.43xvs all stocks
50-Day MA
1.34CADUpdated Sep 29, 2026200-Day MA
1.49CADUpdated Sep 29, 2026Avg 10-Day Volume
513.75KSharesUpdated Sep 29, 2026Avg 30-Day Volume
627.51KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-0.6700CADUpdated Sep 29, 2026Other Income / Expense
-161.59MCADFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule